http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009022096-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b39b36c650e59df3e65f4f16af8f8be http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2800a2e744fc2500a7f80cfd227fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61832b05339e6ae4d32fea67395848aa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4168 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4168 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2008-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1419ccdda192830dfab0dae60eeef07f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69bfba1b5f44c847dc43a05efb8c9c91 |
| publicationDate | 2009-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009022096-A1 |
| titleOfInvention | Drug combinations for the treatment of sialorrhoea |
| abstract | A combination comprises an α2-adrenoceptor agonist and an anti-muscarinic agent for the treatment or prevention of sialorrhoea, for example clozapine-induced sialorrhoea, in a patient subgroup selected from: (I) those suffering from, or at risk of suffering from: (a) a pathological confused mental state; (b) hallucinations; (c) dementia, for example Lewy body dementia; (d) cognitive disturbances; (e) bladder outflow obstruction; (f) prostatism, for example benign prostatic hypertrophy or prostate cancer; (g) glaucoma; (h) hypotension; (i) somnolence; (j) ocular hypertension and (k) needle phobia; or (II) (a) individuals with cortical Lewy bodies; (b) males with an enlarged prostate; (c) individuals with a tendency to presyncope or syncope; (d) individuals with a score ≥ 1 on questions 1.1 and I.2 on the UPDRS or <88/100 on the Cambridge ACE (Addenbrooke's cognitive assessment); (e) individuals with a score ≥ 1 on American Urology Association symptom index; (f) individuals with an intraocular pressure of >20mmHg or taking medication to lower previously raised intraocular pressure; (g) individuals with needle phobia; (h) individuals with a score 1 on Q42 on section C of the UPDRS (unified Parkinson's disease rating scale); (i) individuals with a score 1 on Q41 on section C of the UPDRS; Q) individuals with an ESS (Epworth sleepiness score) of >10; (k) individuals with a leaky blood brain barrier. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8999938-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9259425-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8765758-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8445526-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101891846-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11596600-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8987270-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8952011-B2 |
| priorityDate | 2007-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.